Trimethylamine N-oxide and incident atherosclerotic events in high-risk individuals with diabetes: an ACCORD trial post hoc analysis

Andrea Cardona,1,2 Aaron O’Brien,2 Matthew C Bernier,3 Arpad Somogyi,3 Vicki H Wysocki,3 Suzanne Smart,2 Xin He,4 Giuseppe Ambrosio,5 Willa Ann Hsueh,1,2 Subha V Raman,1,2

ABSTRACT

Introduction Type 2 diabetes mellitus (T2D) confers high atherosclerotic cardiovascular disease (ASCVD) risk. The metabolite trimethylamine N-oxide (TMAO) derived via gut flora has been linked to excess ASCVD.

Research design and methods We analyzed data, biospecimens, and major adverse cardiovascular events (MACEs) from the prospective multicenter randomized Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial to assess its value in 330 high-risk individuals with T2D without evident atherosclerotic disease at enrollment.

Results Incident cardiovascular events occurred in 165 cases; 165 controls matched by age, sex, and treatment arm experienced no incident events during follow-up. Cases and controls (mean age 64.5 years) had similar mean glycated hemoglobin (HbA1c) (8.2%) and mean 10-year ASCVD risk (23.5%); groups also had similar use of statins and antihypertensive medications at baseline and follow-up. Baseline plasma TMAO levels did not differ between groups after adjusting for ASCVD risk score, HbA1c, and estimated glomerular filtration rate, nor did TMAO distinguish patients suffering incident MACE from those who remained event-free.

Conclusions TMAO’s prognostic value for incident ASCVD events may be blunted when applied to individuals with T2D with poor glycemic control and high baseline ASCVD risk. These results behoove further translational investigations of unique mechanisms of ASCVD risk in T2D.

INTRODUCTION

Diabetes mellitus is a major risk factor for atherosclerotic cardiovascular disease (ASCVD), responsible for most cerebrovascular and ischemic heart disease deaths.1 Strategies to mitigate ASCVD risk in individuals with diabetes include lifestyle modifications,2 statins, and novel antidiabetic drugs.3,4 Yet, the population burden of ASCVD remains great, with significant residual risk even in those tolerating high-intensity statins.5,6 While glycemic control is important, the multicenter Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial post hoc analysis.

Significance of this study

What is already known about this subject?

► Patients with type 2 diabetes (T2D) have significant risk of atherosclerotic cardiovascular disease (ASCVD) events like heart attack and stroke. Circulating levels of a metabolite from gut flora called trimethylamine N-oxide (TMAO) has shown association with greater subsequent cardiovascular events in patients with known coronary artery disease (CAD).

What are the new findings?

► In a matched case–control cohort of subjects from the ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial with T2D who did not have CAD at baseline, plasma levels of TMAO did not distinguish those with versus those without incident atherosclerotic events over an average of 4.7 years follow-up.

► This cohort was unique compared with prior studies of TMAO in studying incident events in high-risk patients with poorly controlled T2D.

► Although TMAO levels are known to increase with worsening renal function, it was not able to discriminate among individuals with T2D and normal or near-normal renal function between those with versus those without incident atherosclerotic events.

How might these results change the focus of research or clinical practice?

► Further research is needed to identify targetable metabolites that better predict incident ASCVD events in patients with T2D. Three potential research questions arising from this research include: What metabolites can be identified via untargeted assays to distinguish patients with T2D who suffer incident ASCVD events from those who remain ASCVD event-free? Are there sex differences in ASCVD risk in patients with T2D that could be explained by TMAO? How do newer antidiabetic and lipid-lowering medications impact TMAO’s predictive value for ASCVD risk in T2D?
trial actually found increased mortality with intensive
glycemic control.8 With a global prevalence of type 2
diabetes (T2D) at 8.5% and rising, there is an urgent
need to identify novel, targetable mechanisms of excess
ASCVD risk in T2D.8

One such mechanism may involve the metabolite
trimethylamine N-oxide (TMAO), formed via oxidation
of gut flora-derived trimethylamine.10–13 In patients with
acute coronary syndrome or highly prevalent coronary
artery disease (CAD), higher levels of TMAO were shown
to predict major adverse cardiovascular events (MACEs)
after adjustment for traditional risk factors.14–16 However,
a recent meta-analysis of more than 26 000 subjects noted
significant impact of existing CAD as a covariate: as prev-
ance of CAD increased, so did the reported association
between high TMAO levels and mortality.17

Diabetic individuals without evident baseline ASCVD
were enrolled in the landmark US National Heart, Lung
and Blood Institute (NHLBI)-sponsored ACCORD trial,
and followed over a mean of 3.5 years for incident
ASCVD.8 We leveraged access to ACCORD trial research
data and biospecimens via NHLBI’s Biologic Specimen
and Data Repository Information Coordinating Center
(BioLINCC),18 to test the association between TMAO
level and incident MACE over a long-term follow-up in
individuals with T2D and elevated ASCVD risk but no
baseline ASCVD.

**RESEARCH DESIGN AND METHODS**

**Study design**

The present study represents a post hoc analysis of the
ACCORD trial powered to detect differences in baseline
plasma levels of TMAO in a matched case–control cohort
of subjects with T2D without baseline ASCVD followed
respectively for occurrence of incident MACE. The
NHLBI’s BioLINCC provided access to research data,
as well as plasma samples from the ACCORD trial. The
ACCORD study group has previously published detailed
descriptions of trial design, methods, and study popula-
tion,19 noting that it involved a randomized double 2×2
factorial design conducted at 77 clinical centers across
the USA and Canada (NCT00000620).

**Study population**

We collected data from subjects (age 55–79 years) with
T2D with atherosclerosis risk factors but without baseline
clinical ASCVD, defined in ACCORD as: (1) previous
myocardial infarction (MI) or stroke, (2) coronary or
peripheral revascularization, (3) angina with ischemic
ECG or imaging changes. Enrollment required subjects
to have evidence of at least one of the following: micro-
albuminuria, left ventricular hypertrophy, or two addi-
tional risk factors among dyslipidemia, hypertension,
current smoking, and obesity.19 For the purpose of this
study, the 10-year ASCVD risk score at study entry was
calculated employing the current prevention guidelines
of the American Heart Association and American College
of Cardiology.3

**Outcome and follow-up**

MACE was defined as cardiovascular (CV) death, non-
fatal MI, non-fatal stroke, and any revascularization. Per
ACCORD trial, CV death was defined as death from MI,
heart failure, arrhythmia, invasive CV interventions, CV
causes after non-CV surgery, stroke, unexpected death
presumed to be from ischemic CV disease occurring
within 24 hours after the onset of symptoms, and death
from other vascular diseases (eg, pulmonary emboli,
abdominal aortic aneurysm rupture).19

From ACCORD trial records, 165 subjects with incident
MACE throughout the trial and 165 matched subjects
without incident MACE were identified. BioLINCC
provided all available cases meeting inclusion criteria
with adequate plasma available for assays, and similarly
provided controls matched by age, sex, and ACCORD
treatment arm (ie, intensive vs standard glycemic/blood
pressure/lipid control). MACE outcomes were recorded
at 4-month follow-up intervals until ACCORD trial
completion.

BioLINCC staff used SAS code to select case/controls
through the following process. ACCORD subjects aged
55–79 years at enrollment, without clinical ASCVD and
with specimens of sufficient volume were separated into
two categories: (1) those with any CV death, non-fatal
and fatal stroke, non-fatal MI, non-fatal and fatal conges-
tive heart failure, fatal coronary heart disease, revascu-
larization, or unstable angina event (defined as any of
the following variables having a “0” value: censor_po,
censor_cm, censor_nst, censor_nmi, censor_chf, censor_
tst, censor_maj, censor_ex) and (2) those without the
above events (defined as all the above variables having
a “1” value). Then subjects in category 1 were randomly
matched 1-to-1 with subjects in category 2 as long as they
had the same gender, same treatment arm, and same
value of the baseline_age variable rounded to the nearest
10 (ie, age groups: 55–<65; 65–<75; and 75–79).

To further explore the independent role of TMAO rela-
tive to other risk factors and interventions, we compared
baseline and 24 months of follow-up values for the
following variables: glycated hemoglobin (HbA1c) levels,
total cholesterol, low-density lipoprotein-cholesterol
(LDL), high-density lipoprotein-cholesterol (HDL),
estimated glomerular filtration rate (eGFR), and CV
medications.

We tested the association between levels of TMAO and
incident MACE defined as above (primary outcome). A
secondary analysis was also conducted to evaluate the
relationships among TMAO and hard MACE defined as
CV death, non-fatal MI, and non-fatal stroke.

**Biomarkers**

BioLINCC provided access to the following biomarkers
measured during the study: total cholesterol, LDL, HDL,
triglycerides, HbA1c, serum creatinine, urine creatinine,
Cardiovascular and Metabolic Risk

Table 1  Cohort characteristics at baseline

<table>
<thead>
<tr>
<th></th>
<th>All subjects (N=330)</th>
<th>Case (n=165)</th>
<th>Control (n=165)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age, years</strong></td>
<td>62.7 (58.7–67.5)</td>
<td>62.9 (59.0–67.3)</td>
<td>62.5 (58.5–67.6)</td>
<td>0.781†</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>146 (44)</td>
<td>73 (44)</td>
<td>73 (44)</td>
<td>1.000‡</td>
</tr>
<tr>
<td><strong>Race</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian, n (%)</td>
<td>219 (66)</td>
<td>111 (67)</td>
<td>108 (65)</td>
<td>0.464</td>
</tr>
<tr>
<td>Black, n (%)</td>
<td>53 (16)</td>
<td>27 (16)</td>
<td>26 (16)</td>
<td></td>
</tr>
<tr>
<td>Hispanic, n (%)</td>
<td>22 (7)</td>
<td>13 (8)</td>
<td>9 (5)</td>
<td></td>
</tr>
<tr>
<td>Other, n (%)</td>
<td>36 (11)</td>
<td>14 (8)</td>
<td>22 (13)</td>
<td></td>
</tr>
<tr>
<td><strong>BMI, kg/m²</strong></td>
<td>32.2±5.3</td>
<td>32.0±5.3</td>
<td>32.3±5.4</td>
<td>0.551¶</td>
</tr>
<tr>
<td>Total cholesterol, mg/dL</td>
<td>39 (34–47)</td>
<td>38 (33–47)</td>
<td>41 (36–49)</td>
<td>0.043*</td>
</tr>
<tr>
<td>HDL cholesterol, mg/dL</td>
<td>103 (81–127)</td>
<td>106 (81–131)</td>
<td>102 (81–125)</td>
<td>0.356</td>
</tr>
<tr>
<td>Triglycerides, mg/dL</td>
<td>163 (117–242)</td>
<td>168 (127–261)</td>
<td>159 (112–235)</td>
<td>0.078</td>
</tr>
<tr>
<td>Systolic blood pressure, mm Hg</td>
<td>137±17</td>
<td>139±18</td>
<td>136±17</td>
<td>0.050¶</td>
</tr>
<tr>
<td>HbA1c, %</td>
<td>8.2 (7.6–9.0)</td>
<td>8.3 (7.6–9.2)</td>
<td>8.1 (7.6–8.9)</td>
<td>0.144</td>
</tr>
<tr>
<td>10-year ASCVD risk, %</td>
<td>23.5 (15.3–32.1)</td>
<td>23.4 (15.4–33.3)</td>
<td>23.5 (13.5–30.1)</td>
<td>0.038*</td>
</tr>
<tr>
<td>eGFR, mL/min</td>
<td>88.4 (72.3–104.9)</td>
<td>87.5 (71.8–104.5)</td>
<td>88.9 (73.1–105.1)</td>
<td>0.399</td>
</tr>
<tr>
<td>Fasting plasma glucose, mg/dL</td>
<td>165 (135–200)</td>
<td>162 (132–201)</td>
<td>169 (138–198)</td>
<td>0.801</td>
</tr>
<tr>
<td><strong>Smoking status</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never, n (%)</td>
<td>157 (48)</td>
<td>80 (48)</td>
<td>77 (47)</td>
<td>0.855§</td>
</tr>
<tr>
<td>Former, n (%)</td>
<td>138 (42)</td>
<td>69 (42)</td>
<td>69 (42)</td>
<td></td>
</tr>
<tr>
<td>Current, n (%)</td>
<td>35 (11)</td>
<td>16 (10)</td>
<td>19 (12)</td>
<td></td>
</tr>
<tr>
<td>ACEI and/or ARB, n (%)</td>
<td>226 (68)</td>
<td>114 (69)</td>
<td>112 (68)</td>
<td>0.815‡</td>
</tr>
<tr>
<td>β-blocker, n (%)</td>
<td>73 (22)</td>
<td>38 (23)</td>
<td>35 (21)</td>
<td>0.892‡</td>
</tr>
<tr>
<td>Statin, n (%)</td>
<td>187 (57)</td>
<td>91 (55)</td>
<td>96 (58)</td>
<td>0.653‡</td>
</tr>
<tr>
<td>Antplatelet, n (%)</td>
<td>169 (51)</td>
<td>83 (50)</td>
<td>86 (52)</td>
<td>0.740‡</td>
</tr>
</tbody>
</table>

Variables expressed as mean±SD, median (IQR), or n (%).
*P value <0.05 considered significant.
†Wilcoxon signed rank test.
‡McNemar’s test.
§Marginal homogeneity test for paired subjects.
¶Paired t-test.
ACEI, ACE inhibitor; ARB, angiotensin II receptor blocker; ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

uring albumin, eGFR, fasting plasma glucose, alanine aminotransferase, and serum potassium levels. At enrollment, additional fasting blood samples were appropriately collected and processed for storage, including refrigerated transport and storage at around −80°C. Freeze/thaw cycles were minimized prior to transfer to our laboratory. From frozen biospecimens, we additionally measured high-sensitivity C reactive protein, iron, and ferritin levels.

**Quantification of TMAO**

TMAO was quantified in stored plasma samples with the use of a stable isotope dilution assay and high-performance liquid chromatography (HPLC) with electrospray ionization tandem mass spectrometry (MS), on an UltiMate 3000 HPLC system coupled to a TSQ Quantiva Triple Quadrupole Mass Spectrometer (Thermo Fisher, San Jose, California, USA), using multiple reaction monitoring analysis.20 After thawing, samples underwent methanol protein precipitation, filtration, and dilution in 0.1% formic acid before being passed through an Intakt Scherzo SM-C18 column (100 mm×1 mm, 3 µm particle size, 38°C) at a flow rate of 50 µL/minute. Separation of TMAO was accomplished using an isocratic flow of 80% solvent A (H₂O with 0.1% formic acid) and 20% solvent B (acetonitrile) for 4 min, as published by Petriello et al.21 Sample injection volume was 1 µL. The mass spectrometer was operated in positive electrospray ionization mode set to a capillary voltage of 3.5 kV and a capillary temperature of 300°C. Vaporizer temperature was set to 50°C, sheath gas of 8 arbitrary
Table 2

<table>
<thead>
<tr>
<th>Variables</th>
<th>All subjects at baseline (n=292)</th>
<th>All subjects at follow-up (n=292)</th>
<th>Cases at follow-up (n=146)</th>
<th>Controls at follow-up (n=146)</th>
<th>P1</th>
<th>P2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cholesterol, mg/dL</td>
<td>182 (154–211)</td>
<td>164 (138–199)</td>
<td>162 (137–164)</td>
<td>166 (138–199)</td>
<td>$&lt;0.001^{*}$</td>
<td>0.610†</td>
</tr>
<tr>
<td>HDL cholesterol, mg/dL</td>
<td>39 (34–47)</td>
<td>40 (34–48)</td>
<td>42 (35–52)</td>
<td>86 (70–112)</td>
<td>0.290†</td>
<td>0.350†</td>
</tr>
<tr>
<td>LDL cholesterol, mg/dL</td>
<td>103 (81–126)</td>
<td>87 (70–112)</td>
<td>92 (71–111)</td>
<td>7.0 (6.4–7.8)</td>
<td>$&lt;0.001^{*}$</td>
<td>0.957†</td>
</tr>
<tr>
<td>HbA1c, %</td>
<td>8.2 (6.9–8.9)</td>
<td>7.1 (6.4–7.8)</td>
<td>7.0 (6.3–8.0)</td>
<td>7.0 (6.4–7.8)</td>
<td>$&lt;0.001^{*}$</td>
<td>0.981†</td>
</tr>
<tr>
<td>eGFR, ml/min</td>
<td>89.30 (74.80–105.38)</td>
<td>70.00 (64.20–91.00)</td>
<td>106 (83.98–90.48)</td>
<td>99 (80.64–94.80)</td>
<td>$&lt;0.001^{*}$</td>
<td>0.527†</td>
</tr>
<tr>
<td>ACEI and/or ARB, n (%)</td>
<td>128 (43–47)</td>
<td>103 (68–128)</td>
<td>102 (76–118)</td>
<td>87 (70–112)</td>
<td>0.099†</td>
<td>1.000‡</td>
</tr>
<tr>
<td>Antiplatelet, n (%)</td>
<td>85 (63–66)</td>
<td>165 (79–123)</td>
<td>100 (133)</td>
<td>86 (66–124)</td>
<td>0.001‡</td>
<td>0.659‡</td>
</tr>
</tbody>
</table>

Variables expressed as median (IQR) or n (%).

* P < 0.05 considered significant.
† Wilcoxon signed rank test for matched subjects or repeated measures within each subject.
‡ McNemar’s test or marginal homogeneity tests for categorical variables.

Sample size and power: The hypothesis that TMAO is significantly elevated in subjects with T2D with versus without incident MACE was based on at least a 30% difference. Using these values, the minimum required sample size is 216 (108 per group) with a type I error rate of 0.05% and 80% power.

Data are presented as mean±SD or as median and IQR for continuous variables and as proportions for categorical variables. Paired t-tests were used to compare the matched cases and controls for continuous variables if the normality assumption was not violated. Otherwise, non-parametric Wilcoxon signed-rank tests were conducted. Comparison between matched cases and controls for categorical variables was performed using McNemar’s tests or marginal homogeneity tests. A linear mixed effects regression model was used to test the effect of MACE on plasma levels of TMAO after adjusting for within-pair correlations and multiple covariates. Conditional logistic regression analysis was used to test the predictive power of TMAO on MACE. Statistical significance was set at two-tailed p<0.05. IBM SPSS Statistic 21.0 (Chicago, Illinois, USA) was used for all statistical analyses.

Data and resource availability
The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request. All resources analyzed during the current study are commercially available.

RESULTS
In total, 330 subjects aged 63.5±5.9 years, 44% female, were considered—165 subjects with and 165 subjects without MACE; baseline characteristics are summarized in table 1. Subjects in this cohort were similar to the entire ACCORD population with respect to age, gender, lipid panel, systolic blood pressure, HbA1c levels, creatinine, and fasting plasma glucose levels. At study entry, HbA1c and 10-year ASCVD risk score averaged 8.4% (IQR 7.6%–9.0%) and 23.5% (IQR 15.3%–32.1%), respectively, demonstrating elevated CV risk profile of this population at baseline. MACE-positive and MACE-negative groups were similar with regard to total cholesterol, LDL, eGFR, fasting plasma glucose, and rates of major CV medication use including statin, beta-blocker, antiplatelet and antihypertensive drugs (table 1). After an average of 4.7 years, 181 events occurred in the MACE positive group: 25 CV deaths, 46 non-fatal MIs, units, and auxiliary gas set to 3 arbitrary units. Monitored transitions were as followed: 85.1/66.1 for d9-TMAO and 76.1/59.1 for TMAO, with all collision energies at 25 eV. The mean value of triplicate measurements was recorded for each sample. Detailed methodology for sample preparation and liquid chromatography–mass spectrometry quantification for plasma TMAO is provided as online supplementary material. All the analyses were performed blinded to subjects’ clinical information.
Cardiovascular and Metabolic Risk

Table 3 Biomarker profiles

<table>
<thead>
<tr>
<th></th>
<th>All subjects (N=330)</th>
<th>Cases (n=165)</th>
<th>Controls (n=165)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>hsCRP, mg/L</td>
<td>6.79±9.27</td>
<td>7.04±9.99</td>
<td>6.52±8.48</td>
<td>0.803</td>
</tr>
<tr>
<td>Ferritin, ng/mL</td>
<td>219.31±211.48</td>
<td>218.50±212.40</td>
<td>220.15±211.30</td>
<td>0.581</td>
</tr>
<tr>
<td>Iron, µg/dL</td>
<td>76.38±27.78</td>
<td>75.70±29.19</td>
<td>77.05±26.40</td>
<td>0.308</td>
</tr>
<tr>
<td>ALT, mg/dL</td>
<td>27.40±12.68</td>
<td>25.99±10.33</td>
<td>28.82±14.56</td>
<td>0.167</td>
</tr>
<tr>
<td>Potassium, mmol/L</td>
<td>4.44±0.42</td>
<td>4.48±0.39</td>
<td>4.40±0.45</td>
<td>0.051</td>
</tr>
<tr>
<td>Serum creatinine, mg/dL</td>
<td>0.89±0.22</td>
<td>0.90±0.22</td>
<td>0.88±0.22</td>
<td>0.349</td>
</tr>
<tr>
<td>Urinary creatinine, mg/dL</td>
<td>124.48±67.12</td>
<td>121.01±70.50</td>
<td>127.94±63.59</td>
<td>0.064</td>
</tr>
<tr>
<td>Urinary albumin, mg/dL</td>
<td>11.68±34.32</td>
<td>16.02±44.21</td>
<td>7.34±19.23</td>
<td>0.017*</td>
</tr>
<tr>
<td>Plasma TMAO, µmol/L</td>
<td>7.77 (6.11–9.85)</td>
<td>7.94 (6.10–10.24)</td>
<td>7.70 (6.14–9.57)</td>
<td>0.721</td>
</tr>
</tbody>
</table>

Variables expressed as mean±SD or median (IQR). Paired t-tests or Wilcoxon signed rank tests were used for statistical comparisons. *P value <0.05 considered significant.

ALT, alanine aminotransferase; hsCRP, high-sensitivity C reactive protein; TMAO, trimethylamine N-oxide.

17 non-fatal strokes, and 93 coronary revascularizations. Characteristics at 24-month follow-up are summarized in table 2. Notably, clinical trial participation improved lipid profile, glycemic control and CV medication prescription in the entire cohort. Subjects with versus without MACE had similar total cholesterol, LDL, HbA1c, eGFR, and CV medication status after 2 years (table 2).

Biomarkers

Table 3 summarizes biomarker results showing a trend toward greater albuminuria in cases versus controls but otherwise similar biomarker profiles. Overall, the median plasma TMAO concentration was 7.8 µmol/L (IQR 6.1–9.8). The median plasma TMAO did not differ significantly according to MACE status (p=0.721), levels of 7.9 µmol/L (IQR 6.1–10.2) and 7.7 µmol/L (IQR 6.1–9.6) in MACE-positive and MACE-negative groups, respectively. Based on the linear mixed effects model, MACE status was not significantly associated with plasma levels of TMAO after adjusting for HbA1c, ASCVD risk score, and eGFR (p=0.538). According to the conditional logistic regression model, plasma TMAO was not predictive of MACE outcome (OR 0.991, 95% CI 0.965 to 1.017, p=0.494).

Importantly, we obtained similar results when testing the association between TMAO and hard MACE in a matched case–control subgroup (online supplementary tables S1 and S2). Baseline TMAO also did not distinguish T2D patients with vs without MACE by sex or ethnicity subgroups (figure 1).

DISCUSSION

In the present post hoc analysis of 330 subjects with T2D without baseline ASCVD, half of whom suffered incident ASCVD events, we found no significant difference in baseline TMAO between those with incident events versus matched subjects who remained ASCVD event-free over 4.7 years follow-up despite similar ASCVD and cardiometabolic risk profiles. These findings warrant attention as they are novel, differ from previous publications, and help refine our understanding of TMAO as a potential biomarker for ASCVD events.

Figure 1 In a cohort of subjects from the ACCORD trial with high risk of major adverse cardiovascular events (MACEs), plasma levels of trimethylamine N-oxide (TMAO) at baseline did not distinguish those who went on to suffer a MACE from those who did not (A). Error bars represent IQR. Similarly, no significant differences were found when evaluating by sex (B) or ethnicity (C). AA, African-American; HA, Hispanic American; W, white.
First, the study population is unique for understanding TMAO’s predictive value in a large, well-matched diabetic case–control cohort followed prospectively for incident ASCVD events. Standard risk predictors and commonly employed biomarkers fail to predict CV events when applied to high-risk diabetic subjects. In fact, as our study shows, MACE subgroups were tightly matched for all the major biomarkers commonly adopted to predict CV events including age, gender, 10-year ASCVD risk score, serum creatinine, eGFR, HbA1c levels, and CV medication use at baseline and follow-up. With over 23 million individuals with diabetes in the USA alone who carry an enormous healthcare burden, there is an urgent clinical need to identify novel mechanisms of excess atherosclerosis in T2D that can be targeted to reduce risk.

Our study cohort was particularly well-suited to explore TMAO’s potential to predict incident ASCVD events in stable, high-risk individuals with T2D when commonly used parameters fail to improve risk stratification.

The second important aspect of our cohort was the elevated CV risk profile at study entry, with poor glycemic control (median HbA1c >8.0%), elevated 10-year ASCVD risk score (median >23%), and suboptimal prescription/adherence to proven cardioprotective medical therapies. Importantly, this population profile deserves the greatest attention as it is very much in line with individuals encountered in daily clinical practice: in a recent pooled analysis of more than 2000 diabetic individuals participating in community-based studies, less than 40% were at target for blood pressure, LDL, and HbA1c levels. Thus, as compared with previous studies involving TMA/TMAO, there is a substantial difference in baseline CV risk profile. In a recent study involving subjects with T2D, Tang and colleagues showed that higher plasma TMAO levels were predictive of MACE (death, non-fatal MI, and non-fatal stroke) even after adjusting for other traditional CV risk factors over a period of 3 years of follow-up. However, there are key differences in population profile in the two studies: (1) in our cohort, none of the subjects had CAD at baseline, as compared with almost 50% prevalence in that work where nearly half had a history of prior MI and approximately one-third had previously undergone coronary revascularization; (2) HbA1c levels are substantially different with baseline HbA1c required to be >7.5% for enrollment in ACCORD, compared with HbA1c levels spread over a wide range with a significant proportion of subjects with good glycemic control (HbA1c<6.5%); (3) TMAO levels in our study were significantly higher, averaging 7.8 (6.1–9.8) µmol/L compared with 4.4 (IQR 2.8–7.7) µmol/L in the prior study. This is not surprising, as TMAO levels tend to track HbA1c levels.

Another important relationship to note is that TMAO levels increase with worsening renal function. In Tang’s study, renal function was significantly lower in the tertile of higher TMAO levels (eGFR 61 (45–82) mL/min/1.73 m²), which was set as reference to calculate the association with MACE outcome. In our study, we did not have this important confounder effect as the entire cohort demonstrated normal or close to normal eGFR levels and did not differ by MACE status. We further note prior work that indicated a mortality association in patients with eGFR <90 mL/min/1.73 m² in a cohort without the severity of diabetes as in this study.

Analyzed together, these two studies help to refine the role of TMAO in T2D. In fact, while TMAO seems to have a powerful predictive value for MACE in T2D populations characterized by high prevalence of CAD and good glycemic control, the discriminatory power of TMAO appears to be lost when measured in subjects with T2D without evident CAD but high ASCVD risk and poor glycemic control.

As TMAO showed no relationship to incident ASCVD events in our study population of high-risk subjects with T2D but without baseline CAD, negative findings have also been recorded in other cohorts. Mueller and colleagues, studying 339 patients undergoing coronary angiography for the evaluation of suspected CAD, found no association between levels of TMAO and incident CV events during 8 years of follow-up. Similarly, negative results have been recorded in cohorts with chronic kidney disease and heart failure.

The collective evidence to date on TMAO underscores the importance of assessing the entire cardiometabolic profile of diabetic individuals. Their TMAO levels are influenced by renal function, diet, gut microbiome, history of CAD and glycemic control. Our cases and controls were tightly matched for renal function (mostly normal in the two groups) with similar levels of HbA1c and no history of CAD. In this scenario, TMAO did not emerge as a biomarker predictive of ASCVD events.

Limitations

The study was not powered for sensitivity analyses based on sex, underscoring the need to assess TMAO’s prognostic significance in diabetic women versus men in a larger cohort. We also do not know if groups differed in dietary choline and L-carnitine intake, though lack of difference cannot be attributed to variations in standard of care between groups since rates of cardioprotective medication prescriptions at follow-up were similar. Formation of trimethylamine—TMAO’s antecedent—depends on intestinal microbes encountering suitable precursors in the diet. Assessment of diet, host genetics, and antibiotic therapy, all of which significantly influence the gut microbiome, is warranted in future studies. Focusing on incident events, we did not assay biospecimens at follow-up for TMA/TMAO to inform our understanding of change in these biomarkers over time. TMAO warrants long-term, prospective evaluation in high-risk diabetic individuals receiving newer antidiabetic and lipid-lowering medications compared with the treatment regimens used in ACCORD.
Conclusions
In a cohort of stable high-risk subjects with T2D matched for age, sex, and glycemic control with very similar CV risk profiles, plasma levels of TMAO were not associated with MACE over 4.7 years of follow-up. TMAO’s prognostic value for incident ASCVD events appears to be blunted when applied to diabetic subjects without established CAD but with poor glycemic control and high baseline ASCVD risk.

Author affiliations
1Department of Internal Medicine, Ohio State University, Columbus, Ohio, USA
2Davis Heart and Lung Research Institute, Ohio State University, Columbus, Ohio, USA
3Carnegie Mellon School of Medicine, Pittsburgh, PA, USA
4Department of Epidemiology and Biostatistics, University of Maryland at College Park, College Park, Maryland, USA
5Division of Cardiology, University of Perugia School of Medicine and Surgery, Perugia, Italy

Acknowledgements
The authors thank the NHLBI’s BioLINCC for its assistance.

Contributors
AC: study design, biospecimen analysis, data interpretation, data analysis and manuscript writing; AO: biospecimen analysis, data interpretation, data analysis and manuscript writing; MCB: biospecimen analysis, data analysis and manuscript writing; AS: biospecimen analysis, data interpretation, data analysis and manuscript writing; XR: data analysis and statistical analysis; GA: study design, biospecimen analysis, data interpretation, data analysis and manuscript writing; WH: data interpretation and manuscript writing; DJ: study design, biospecimen analysis, data interpretation, data analysis and manuscript writing. Principal investigator, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Funding
This work was supported by the US National Center for Advancing Translational Sciences (UL1TR002733).

Competing interests
AC was recipient of a grant-in-aid by Fondazione Umberto Veronesi, Italy.

Patient consent for publication
Not required.

Provenance and peer review
Not commissioned; externally peer reviewed.

Data availability statement
Data are available on reasonable request.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Suzanne Smart http://orcid.org/0000-0002-5288-8430
Willa Ann Haehl http://orcid.org/0000-0002-7321-4198
Subha V Raman http://orcid.org/0000-0002-6013-0689

REFERENCES
Cardiovascular and Metabolic Risk

